BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 20660332)

  • 1. Expression of LMO2 is associated with t(14;18)/IGH-BCL2 fusion but not BCL6 translocations in diffuse large B-cell lymphoma.
    Durnick DK; Law ME; Maurer MJ; Natkunam Y; Levy R; Lossos IS; Kurtin PJ; McPhail ED
    Am J Clin Pathol; 2010 Aug; 134(2):278-81. PubMed ID: 20660332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Translocations involving the immunoglobulin heavy chain gene locus predict better survival in gastric diffuse large B-cell lymphoma.
    Nakamura S; Ye H; Bacon CM; Goatly A; Liu H; Kerr L; Banham AH; Streubel B; Yao T; Tsuneyoshi M; Savio A; Takeshita M; Dartigues P; Ruskoné-Fourmestraux A; Matsumoto T; Iida M; Du MQ
    Clin Cancer Res; 2008 May; 14(10):3002-10. PubMed ID: 18445693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The spectrum of B-cell non-Hodgkin lymphomas with dual IgH-BCL2 and BCL6 translocations.
    Keller CE; Nandula S; Fisher J; Subramaniyam S; Vakiani E; Savage DG; Murty VV; Alobeid B; Bhagat G
    Am J Clin Pathol; 2008 Aug; 130(2):193-201. PubMed ID: 18628087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diffuse large B-cell lymphoma with extra Bcl-2 gene signals detected by FISH analysis is associated with a "non-germinal center phenotype".
    Kusumoto S; Kobayashi Y; Sekiguchi N; Tanimoto K; Onishi Y; Yokota Y; Watanabe T; Maeshima AM; Ishida T; Inagaki H; Matsuno Y; Ueda R; Tobinai K
    Am J Surg Pathol; 2005 Aug; 29(8):1067-73. PubMed ID: 16006802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.
    Copie-Bergman C; Gaulard P; Leroy K; Briere J; Baia M; Jais JP; Salles GA; Berger F; Haioun C; Tilly H; Emile JF; Banham AH; Mounier N; Gisselbrecht C; Feugier P; Coiffier B; Molina TJ
    J Clin Oncol; 2009 Nov; 27(33):5573-9. PubMed ID: 19786664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma.
    Obermann EC; Csato M; Dirnhofer S; Tzankov A
    J Clin Pathol; 2009 Oct; 62(10):903-7. PubMed ID: 19783718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome.
    Barrans SL; Evans PA; O'Connor SJ; Kendall SJ; Owen RG; Haynes AP; Morgan GJ; Jack AS
    Clin Cancer Res; 2003 Jun; 9(6):2133-9. PubMed ID: 12796378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunophenotyping and molecular genetic analysis of diffuse large B-cell lymphoma].
    Han YS; Xue YQ; Yang HY; Zhang J; Pan JL
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Apr; 30(2):143-7. PubMed ID: 23568722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma.
    Iqbal J; Neppalli VT; Wright G; Dave BJ; Horsman DE; Rosenwald A; Lynch J; Hans CP; Weisenburger DD; Greiner TC; Gascoyne RD; Campo E; Ott G; Müller-Hermelink HK; Delabie J; Jaffe ES; Grogan TM; Connors JM; Vose JM; Armitage JO; Staudt LM; Chan WC
    J Clin Oncol; 2006 Feb; 24(6):961-8. PubMed ID: 16418494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The gene for interleukin-21 receptor is the partner of BCL6 in t(3;16)(q27;p11), which is recurrently observed in diffuse large B-cell lymphoma.
    Ueda C; Akasaka T; Kurata M; Maesako Y; Nishikori M; Ichinohasama R; Imada K; Uchiyama T; Ohno H
    Oncogene; 2002 Jan; 21(3):368-76. PubMed ID: 11821949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gain of chromosome region 18q21 including the MALT1 gene is associated with the activated B-cell-like gene expression subtype and increased BCL2 gene dosage and protein expression in diffuse large B-cell lymphoma.
    Dierlamm J; Murga Penas EM; Bentink S; Wessendorf S; Berger H; Hummel M; Klapper W; Lenze D; Rosenwald A; Haralambieva E; Ott G; Cogliatti SB; Möller P; Schwaenen C; Stein H; Löffler M; Spang R; Trümper L; Siebert R;
    Haematologica; 2008 May; 93(5):688-96. PubMed ID: 18367485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
    Natkunam Y; Farinha P; Hsi ED; Hans CP; Tibshirani R; Sehn LH; Connors JM; Gratzinger D; Rosado M; Zhao S; Pohlman B; Wongchaowart N; Bast M; Avigdor A; Schiby G; Nagler A; Byrne GE; Levy R; Gascoyne RD; Lossos IS
    J Clin Oncol; 2008 Jan; 26(3):447-54. PubMed ID: 18086797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Derivative (3)t(3;18)(q27;q21)t(18;16)(q21;?) involving the BCL2 and BCL6 genes in follicular lymphoma with t(3;14;18)(q27;q32;q21).
    Yamamoto K; Ono K; Katayama Y; Shimoyama M; Matsui T
    Cancer Genet Cytogenet; 2007 Nov; 179(1):69-75. PubMed ID: 17981218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel t(3;8)(q27;q24.1) simultaneously involving both the BCL6 and MYC genes in a diffuse large B-cell lymphoma.
    Wang HY; Bossler AD; Schaffer A; Tomczak E; DiPatri D; Frank DM; Nowell PC; Bagg A
    Cancer Genet Cytogenet; 2007 Jan; 172(1):45-53. PubMed ID: 17175379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.
    Yoon SO; Jeon YK; Paik JH; Kim WY; Kim YA; Kim JE; Kim CW
    Histopathology; 2008 Aug; 53(2):205-17. PubMed ID: 18752503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma.
    Iqbal J; Greiner TC; Patel K; Dave BJ; Smith L; Ji J; Wright G; Sanger WG; Pickering DL; Jain S; Horsman DE; Shen Y; Fu K; Weisenburger DD; Hans CP; Campo E; Gascoyne RD; Rosenwald A; Jaffe ES; Delabie J; Rimsza L; Ott G; Müller-Hermelink HK; Connors JM; Vose JM; McKeithan T; Staudt LM; Chan WC;
    Leukemia; 2007 Nov; 21(11):2332-43. PubMed ID: 17625604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular features of a new human lymphoma cell line carrying both BCL2 and BCL6 gene rearrangements.
    Yonetani N; Akasaka T; Akasaka H; Ohno H; Okuma M; Miura I; Takahashi N; Miyanishi S; Okumura A; Muramatsu M; Fukuhara S
    Oncogene; 1998 Aug; 17(8):971-9. PubMed ID: 9747876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. t(14;18)(q32;q21) involving IGH and MALT1 is uncommon in cutaneous MALT lymphomas and primary cutaneous diffuse large B-cell lymphomas.
    Wongchaowart NT; Kim B; Hsi ED; Swerdlow SH; Tubbs RR; Cook JR
    J Cutan Pathol; 2006 Apr; 33(4):286-92. PubMed ID: 16630178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased expression of the bcl6 and CD10 proteins is associated with increased apoptosis and proliferation in diffuse large B-cell lymphomas.
    Bai M; Agnantis NJ; Skyrlas A; Tsanou E; Kamina S; Galani V; Kanavaros P
    Mod Pathol; 2003 May; 16(5):471-80. PubMed ID: 12748254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amplification of IGH/MYC fusion in clinically aggressive IGH/BCL2-positive germinal center B-cell lymphomas.
    Martín-Subero JI; Odero MD; Hernandez R; Cigudosa JC; Agirre X; Saez B; Sanz-García E; Ardanaz MT; Novo FJ; Gascoyne RD; Calasanz MJ; Siebert R
    Genes Chromosomes Cancer; 2005 Aug; 43(4):414-23. PubMed ID: 15852472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.